6160 Stock Overview
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BeiGene, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$115.60 |
| 52 Week High | US$153.00 |
| 52 Week Low | US$75.45 |
| Beta | 0.63 |
| 11 Month Change | -9.90% |
| 3 Month Change | -5.09% |
| 1 Year Change | 4.14% |
| 33 Year Change | -45.37% |
| 5 Year Change | n/a |
| Change since IPO | -16.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6160 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 3.1% | 5.5% | -2.1% |
| 1Y | 4.1% | -12.8% | 9.7% |
Return vs Industry: 6160 exceeded the Hong Kong Biotechs industry which returned -15.2% over the past year.
Return vs Market: 6160 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 6160 volatility | |
|---|---|
| 6160 Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.1% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 6160 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6160's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 10,000 | John Oyler | www.beigene.com |
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company’s clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor.
BeiGene, Ltd. Fundamentals Summary
| 6160 fundamental statistics | |
|---|---|
| Market cap | HK$157.49b |
| Earnings (TTM) | -HK$6.44b |
| Revenue (TTM) | HK$25.25b |
6.2x
P/S Ratio-24.5x
P/E RatioIs 6160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6160 income statement (TTM) | |
|---|---|
| Revenue | CN¥23.51b |
| Cost of Revenue | CN¥3.84b |
| Gross Profit | CN¥19.67b |
| Other Expenses | CN¥25.66b |
| Earnings | -CN¥5.99b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -56.41 |
| Gross Margin | 83.67% |
| Net Profit Margin | -25.50% |
| Debt/Equity Ratio | 29.6% |
How did 6160 perform over the long term?
See historical performance and comparison